Advanced Search

Technical Analysis for ARQT - Arcutis Biotherapeutics, Inc.

Grade Last Price % Change Price Change
grade D 28.29 2.61% 0.72
ARQT closed up 2.61 percent on Tuesday, July 14, 2020, on 88 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
0 Watchers
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical ARQT trend table...
Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Resistance Bearish 2.61%
MACD Bearish Centerline Cross Bearish 2.61%
Oversold Stochastic Weakness 2.61%
50 DMA Resistance Bearish -2.75%
Multiple of Ten Bearish Other -2.75%
Oversold Stochastic Weakness -2.75%
Fell Below 20 DMA Bearish -2.62%
Fell Below 50 DMA Bearish -2.62%
Older EOD signals for ARQT ...
View Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators Basic chart:

Profile

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
Medical Specialties Immunology Organ Systems Autoimmune Diseases Psoriasis Atopic Dermatitis Dermatitis Atopy Eczema Type I Hypersensitivity Dermatological Diseases Vitiligo

Is ARQT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Jul 13 Arcutis initiates enrollment in mid-stage study of ARQ-252 in hand eczema
Jul 13 Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema
Jun 22 Is Arcutis Biotherapeutics, Inc. (ARQT) Going to Burn These Hedge Funds?
Jun 22 Arcutis enrolls last patient in mid-stage ARQ-154 trial for seborrheic dermatitis
Jun 22 Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis
Jun 10 Arcutis to Present at the Goldman Sachs 41st Annual Global Health Care Conference
Jun 1 Ayisha Jeter Joins Arcutis as Vice President of Market Access
May 27 Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and Operations
May 12 Arcutis Biotherapeutics EPS misses by $0.29
May 12 Arcutis Announces First Quarter 2020 Financial Results and Provides Business Update
See more ARQT news...

Indicators

Indicator Value
52 Week High 40.88
52 Week Low 17.1
Average Volume 86,516
200-Day Moving Average 0.00
50-Day Moving Average 29.48
20-Day Moving Average 31.25
10-Day Moving Average 30.36
Average True Range 2.86
ADX 16.43
+DI 17.33
-DI 23.20
Chandelier Exit (Long, 3 ATRs ) 31.28
Chandelier Exit (Short, 3 ATRs ) 33.58
Upper Bollinger Band 35.52
Lower Bollinger Band 26.98
Percent B (%b) 0.15
BandWidth 27.34
MACD Line -0.26
MACD Signal Line 0.32
MACD Histogram -0.5835
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.62
Resistance 3 (R3) 30.48 29.58 30.23
Resistance 2 (R2) 29.58 28.98 29.64 30.10
Resistance 1 (R1) 28.93 28.62 29.26 29.07 29.97
Pivot Point 28.03 28.03 28.19 28.09 28.03
Support 1 (S1) 27.38 27.43 27.71 27.52 26.61
Support 2 (S2) 26.48 27.07 26.54 26.48
Support 3 (S3) 25.83 26.48 26.35
Support 4 (S4) 25.97